Paradigm Biopharmaceuticals Limited (PBIGF)
OTCMKTS · Delayed Price · Currency is USD
0.2300
0.00 (0.00%)
At close: Feb 10, 2026
PBIGF Revenue
Paradigm Biopharmaceuticals had revenue of -16.70K AUD in the half year ending June 30, 2025.
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
93.82M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | - | - | - |
| Jun 30, 2024 | - | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 79.22K | 58.67K | 285.52% |
| Jun 30, 2021 | 20.55K | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Harvard Apparatus Regenerative Technology | 743.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 198.11K |
Paradigm Biopharmaceuticals News
- 3 years ago - Australia's Paradigm Biopharmaceuticals says phase 2 trial in osteoarthritis shows signs of disease modification at 6-month follow-up - GlobeNewsWire
- 3 years ago - PARADIGM BIOPHARMACEUTICALS LTD. APPOINTS MARCO POLIZZI as CHIEF EXECUTIVE OFFICER - PRNewsWire
- 4 years ago - PARADIGM BIOPHARMACEUTICALS SPOTLIGHTS POTENTIAL BREAKTHROUGH OSTEOARTHRITIS TREATMENT AT BIOLOGICAL ASSOCIATION 3RD ANNUAL SUMMIT - PRNewsWire
- 4 years ago - Paradigm Biopharmaceuticals Retains Rubenstein Public Relations as Agency of Record - PRNewsWire
- 4 years ago - FDA Grants Fast Track Designation for Paradigm Biopharmaceuticals Phase III Osteoarthritis Program - PRNewsWire
- 4 years ago - Paradigm Biopharmaceuticals Initiates a Phase 3 Clinical Trial in Knee Osteoarthritis Across the U.S - PRNewsWire